Clinical Trial Update: Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML [Phase 1]

View source ↗

Summary

Phase 1 clinical trial completed evaluating the safety of IL-21–stimulated natural killer (NK) cells for induction in relapsed/refractory acute myeloid leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IL-21 NK cells

Snippet

Sponsor: Sumithira Vasu | Conditions: Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Status: COMPLETED